醒脑静注射液对急性脑梗死血瘀证患者疗效及相关指标的影响 点击下载
| 论文标题： | 醒脑静注射液对急性脑梗死血瘀证患者疗效及相关指标的影响 |
| 英文标题： | |
| 中文摘要： | 目的：探讨醒脑静注射液对急性脑梗死血瘀证患者疗效及相关指标的影响。方法：70例急性脑梗死血瘀证患者随机分为对照组（35例）和观察组（35例）。对照组患者按照《中国急性缺血性脑卒中诊治指南（2014）》常规治疗，在溶栓时间窗内静脉输注重组人组织型纤溶酶原激活剂，超过溶栓时间窗者每晚口服拜阿司匹林肠溶片0.3 g， 1周后改为每晚0.1 g+每晚口服阿托伐他汀钙片40 mg，如患者存在吞咽困难可经胃管给药。观察组患者在对照组治疗的基础上给予醒脑静注射液30 ml加入0.9％氯化钠注射液250 ml中静脉滴注，每日1次。两组疗程均为14 d。观察两组患者的临床疗效，治疗前后的γ干扰素（IFN-γ）、白细胞介素（IL）-13、IL-4、超敏C反应蛋白（hs-CRP）水平，美国国立卫生院卒中量表（NIHSS）评分、改良Barthel（BI）指数评分、脑梗死体积及不良反应发生情况。结果：两组患者总有效率、不良反应发生率比较，差异均无统计学意义（P＞0.05）。治疗前，两组患者IFN-γ、IL-13、IL-4、hs-CRP水平及NIHSS评分、BI指数评分、脑梗死体积比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者IFN-γ、hs-CRP水平及NIHSS评分、脑梗死体积均显著低于同组治疗前，且观察组低于对照组，IL-13、IL-4水平及BI指数评分均显著高于同组治疗前，且观察组高于对照组，差异均有统计学意义（P＜0.05或P＜0.01）。结论：在常规治疗的基础上，醒脑静注射液治疗急性脑梗死血瘀证的疗效显著，可降低患者炎症因子水平，改善其神经功能缺损、日常生活能力及脑梗死体积，且安全性较好。 |
| 英文摘要： | OBJECTIVE： To observe the effects of Xingnaojing injection on the efficacy and safety of patients with acute cerebral infarction merge blood stasis syndrome. METHODS： 70 patients with acute cerebral infarction merge blood stasis syndrome were randomly divided into observation group （35 cases） and control group （35 cases）. Control group received conventional treatment according to 2014 edition of Chinese guideline for diagnosis and management of acute ischemic stooke. Patients within thrombolysis time window were given intravenaus infusion of rt-PA， and those out of thrombolysis time window orally received 0.3 g Aspirin tablet every evening， then 0.1 g after 1 week+40 mg Atorvastatin calcium tablet every evening，and if patients have arfficulty suallowing，gavage administiation was implemented. Observation group additionally received 30 ml Xingnaojing injection， adding into 250 ml 0.9％ Sodium chloride injection， intravenous infusion， once a day. The treatment course for both groups was 14 d. Clinical efficacy， γ-interferon （IFN-γ）， interleukin-13 （IL-13）， interleukin-4 （IL-4）， high-sensitivity C-reactive protein （hs-CRP） levels， the US National Institutes of Health Stroke Scale （NIHSS） rating， improved Barthel index （BI）， infarction size before and after treatment and the incidence of adverse reactions in 2 groups were observed. RESULTS： There was no significant difference in the total effective rate and incidence of adverse reactions in 2 groups （P＞0.05）. Before treatment， there were no significant differences in IFN-γ， IL-13， IL-4， hs-CRP levels， the NIHSS rating， BI and infarction size in 2 groups （P＞0.05）. After treatment， the IFN-γ， hs-CRP levels， the NIHSS rating and infarction size in 2 groups were significantly lower than before， and observation group was lower than control group， IL-13， IL-4 and BI were significantly higher than before， and observation group was higher than control group， the differences were statistically significant （P＜0.05 or P＜0.01）. CONCLUSIONS： Based on conventional treatment， Xingnaojing injection shows obvious efficacy the efficacy and safety of patients with acute cerebral infarction merge blood stasis syndrome， it can reduce the levels of inflammatory cytokines， improve neurological deficits， daily living skills and infarct volume， with good safety. |
| 期刊： | 2016年第27卷第21期 |
| 作者： | 卢志刚，刘芸 |
| 英文作者： | LU Zhigang，LIU Yun |
| 关键字： | 醒脑静注射液；急性脑梗死；血瘀证；炎症因子；疗效；安全性 |
| KEYWORDS： | Xingnaojing injection； Acute cerebral infarction； Blood stasis syndrome； Inflammatory cytokines； Efficacy； Safety |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！